Literature DB >> 29316358

Continuous intravenous sildenafil as an early treatment in neonates with congenital diaphragmatic hernia.

Florian Kipfmueller1, Lukas Schroeder1, Christoph Berg2, Katrin Heindel1, Peter Bartmann1, Andreas Mueller1.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is an important contributor of morbidity and mortality in infants with congenital diaphragmatic hernia (CDH). Treatment options are limited, but sildenafil might improve oxygenation and PH in neonates with CDH.
OBJECTIVE: Aim of this study is to assess effects of intravenous sildenafil on oxygenation and PH in neonates with CDH.
METHODS: A retrospective chart review was performed in all neonates with CDH born in our institution between September 2012 and December 2014. Indication for sildenafil was an OI > 15, PH > 2/3 systemic pressure, or a difference in pre- and postductal oxygen saturation (≥8%). A sildenafil bolus was administered followed by a maintenance infusion of 1.6 mg/kg/d. Primary outcome was improved oxygenation after starting sildenafil. Patients were compared according to improvement in oxygenation (responder vs non-responder).
RESULTS: A total of 26 of 44 neonates were treated with intravenous sildenafil and in all sildenafil were initiated within the first 24 h of life (median age 3.1 h). Improved oxygenation was observed in 11 infants (42.3%). Among the 15 non-responders (57.6%) ECMO was started in 13 and two infants died without ECMO. Vasopressor support increased significantly during the first hours after commencing sildenafil in responders and non-responders. Echocardiographic indices demonstrated an effect on pulmonary arterial pressure within the first 24 h after starting sildenafil.
CONCLUSIONS: Treatment of neonates with intravenous sildenafil during the first day of life was associated with acute improvement in oxygenation in more than 40% of patients. However, a significant increase in vasopressor support was observed.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  ECMO; hemodynamics; oxygenation; phosphodiesterase 5 inhibitor

Mesh:

Substances:

Year:  2018        PMID: 29316358     DOI: 10.1002/ppul.23935

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  11 in total

1.  Treatment of pulmonary hypertension during initial hospitalization in a multicenter cohort of infants with congenital diaphragmatic hernia (CDH).

Authors:  Ruth B Seabrook; Theresa R Grover; Natalie Rintoul; Mark Weems; Sarah Keene; Beverly Brozanski; Robert DiGeronimo; Beth Haberman; Holly Hedrick; Jason Gien; Noorjahan Ali; Rachel Chapman; John Daniel; H Allen Harrison; Yvette Johnson; Nicolas F M Porta; Michael Uhing; Isabella Zaniletti; Karna Murthy
Journal:  J Perinatol       Date:  2021-03-01       Impact factor: 2.521

2.  Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia.

Authors:  Suzan C M Cochius-den Otter; Florian Kipfmueller; Brenda C M de Winter; Karel Allegaert; Dick Tibboel; Andreas Mueller; Birgit C P Koch
Journal:  Eur J Clin Pharmacol       Date:  2019-11-18       Impact factor: 2.953

Review 3.  Congenital diaphragmatic hernia.

Authors:  Augusto Zani; Wendy K Chung; Jan Deprest; Matthew T Harting; Tim Jancelewicz; Shaun M Kunisaki; Neil Patel; Lina Antounians; Pramod S Puligandla; Richard Keijzer
Journal:  Nat Rev Dis Primers       Date:  2022-06-01       Impact factor: 52.329

4.  Echocardiographic Assessment of Pulmonary Hypertension in Neonates with Congenital Diaphragmatic Hernia Using Pulmonary Artery Flow Characteristics.

Authors:  Florian Kipfmueller; Suemeyra Akkas; Flaminia Pugnaloni; Bartolomeo Bo; Lotte Lemloh; Lukas Schroeder; Ulrich Gembruch; Annegret Geipel; Christoph Berg; Andreas Heydweiller; Andreas Mueller
Journal:  J Clin Med       Date:  2022-05-27       Impact factor: 4.964

Review 5.  Management of Pulmonary Arterial Hypertension in the Pediatric Patient.

Authors:  Jordan E Ezekian; Kevin D Hill
Journal:  Curr Cardiol Rep       Date:  2019-11-28       Impact factor: 2.931

Review 6.  Challenges and Pitfalls: Performing Clinical Trials in Patients With Congenital Diaphragmatic Hernia.

Authors:  Suzan Cochius-den Otter; Jan A Deprest; Laurent Storme; Anne Greenough; Dick Tibboel
Journal:  Front Pediatr       Date:  2022-04-15       Impact factor: 3.569

7.  The CoDiNOS trial protocol: an international randomised controlled trial of intravenous sildenafil versus inhaled nitric oxide for the treatment of pulmonary hypertension in neonates with congenital diaphragmatic hernia.

Authors:  Suzan Cochius-den Otter; Thomas Schaible; Anne Greenough; Arno van Heijst; Neil Patel; Karel Allegaert; Joost van Rosmalen; Dick Tibboel
Journal:  BMJ Open       Date:  2019-11-05       Impact factor: 2.692

Review 8.  Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models.

Authors:  Kathleen Marulanda; Nick D Tsihlis; Sean E McLean; Melina R Kibbe
Journal:  Pediatr Res       Date:  2020-10-10       Impact factor: 3.756

Review 9.  Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm.

Authors:  Feriel Fortas; Matteo Di Nardo; Nadya Yousef; Marc Humbert; Daniele De Luca
Journal:  Eur J Pediatr       Date:  2021-06-06       Impact factor: 3.183

Review 10.  Congenital diaphragmatic hernia: a narrative review of controversies in neonatal management.

Authors:  Michelle J Yang; Katie W Russell; Bradley A Yoder; Stephen J Fenton
Journal:  Transl Pediatr       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.